Dec 9 (Reuters) - CVS Health (CVS) on Tuesday forecast 2026 profit above Wall Street estimates and this year's projected earnings, signalling steady progress in the health conglomerate's turnaround plan.
CVS stock rose 5% in early trading on Tuesday.
The company in October projected double-digit earnings growth for 2026 after raising its 2025 profit forecast for the third time.
"We are closing out 2025 with meaningful momentum across our businesses and we expect another year of strong earnings growth in 2026," said Chief Financial Officer Brian Newman on Tuesday.
The company forecast 2026 adjusted profit to be in the range of $7.00 to $7.20 per share, compared with analysts' average estimate of $7.16, according to data compiled by LSEG.
It, however, expects total revenue of at least $400 billion next year, below analysts' average estimate of $419.26 billion.
CVS also raised its 2025 adjusted profit forecast to $6.60 to $6.70 per share from $6.55 to $6.65 previously.
(Reporting by Sneha S K in Bengaluru; Editing by Shinjini Ganguli)
LATEST POSTS
- 1
6 Top Computer game Control center - 2'No middle ground' for tackling antisemitism after Bondi Beach mass shooting, deputy FM Haskel says
- 3Surprise! Saturn's huge moon Titan may not have a buried ocean after all
- 4Pick Your #1 Kind Of Bread
- 5AI’s errors may be impossible to eliminate – what that means for its use in health care
- Displaced Palestinian families suffer as heavy rains flood Gaza tent camps
- Japan deploys the military to counter a surge in bear attacks
- Over 60 local leaders push Netanyahu to halt haredi draft bill, warn of social rift
- Figure out How to Assess the Unwavering quality of SUVs for Seniors
- Forum Dvorah demands clear support for women in combat as IDF gender debate escalates
- 4 Electric Vehicle Brands: Execution, Unwavering quality, and Development
- Climate change is straining Alaska's Arctic. A new mining road may push the region past the brink
- Sports Shoes of 2024: Upgrade Execution and Solace
- RFK Jr. succeeds in changing hepatitis B recommendation | The Excerpt
